SCHEMBL4338380

SCHEMBL4338380

Cc1cc(=O)n(-c2ccc(C(F)(F)F)cc2)[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.63
ALDH1A1 P00352 6/20 0.63
KDM4E B2RXH2 4/20 0.63
KMT2A Q03164 4/20 0.63
GAA P10253 2/20 0.63
HTT P42858 2/20 0.63
MEN1 O00255 1/20 0.63
LMNA P02545 2/20 0.59
RECQL P46063 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
TRPV1 Q8NER1 4/20 0.49
ALKBH5 Q6P6C2 2/20 0.45
RAD51 Q06609 1/20 0.42
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
IDH1 O75874 1/20 0.41
ALPL P05186 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344344 0.85 ALDH1A1 (0.65) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL4338425 0.83 ALKBH5 (0.64) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL486233 0.81 ALDH1A1 (0.69) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL486125 0.80 MAPT (0.73) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL5203012 0.77 ALDH1A1 (0.69) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL486340 0.77 ALDH1A1 (0.69) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL8166341 0.77 ALDH1A1 (0.69) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL8592651 0.77 ALDH1A1 (0.69) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL5976522 0.77 KDM4E (0.44) MAPTALDH1A1KDM4EKMT2AGAA
SCHEMBL5425653 0.77 ALDH1A1 (0.68) MAPTALDH1A1KDM4EKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3892734-B1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2024-08-28 EP disclosed
EP-3892734-A1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION Ludwig-Maximilians-Universität München (DE) 2021-10-13 EP disclosed
EP-3892734-A1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION Ludwig-Maximilians-Universität München (DE) 2021-10-13 EP disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
US-6670387-B1 Thrombocytopenia; hydroxy-1-azo-naphthalene derivatives; 3-hydroxy-4-((2-hydroxy-1-naphthalenyl)azo-)-1-naphthalenesul fonic acid; promoters of thrombopoiesis and megakaryocytopoi esis; enhancing platelet production; agonizing TPO receptor SMITHKLINE BEECHAM CORPORATION 2003-12-30 US disclosed
EP-1156804-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2002-08-07 EP disclosed
EP-1156804-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-28 EP disclosed
WO-2000035446-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2000-06-22 WO disclosed
US-5162528-A Pre- and post-emergence; phytaphthora in tomato plants; rice and wheat BAYER AKTIENGESELLSCHAFT (DE) 1992-11-10 US disclosed
US-5028717-A Herbicidal and fungicidal agents based on substituted pyrazolin-5-one derivatives BAYER AKTIENGESELLSCHAFT (DE) 1991-07-02 US disclosed
US-4909827-A Containing a C6-10 aryl group substituted in position 1 BAYER AKTIENGESELLSCHAFT (DE) 1990-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885KDM4E 3202/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885ALDH1A1 1012/4885KDM4E 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.